Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with t
Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
ASML, Sandisk, Micron, and other AI stocks struggle as investors fret over rising costs and competition from China.
The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more
Micron, Nvidia, and other AI stocks struggle as investors fret about rising costs and competition from China.
Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.
View interactive chart, options flow, and AI analysis for JNJ on Zorveq Finance.
Open JNJ Chart & Analysis →